ContraVir appoints new CMO
This article was originally published in Scrip
ContraVir Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, has named Dr John Sullivan-Bolyai chief medical officer. Most recently, Dr Sullivan-Bolyai was the executive director of infectious disease clinical research at Merck where he oversaw multiple HCV protocols in all three phases of clinical development. Prior to this, he was the vice-president of clinical research at Idenix.
You may also be interested in...
Two deals have resulted in the formerly shingles-focused biotech beginning to build an HBV pipeline and look ahead to therapeutic advances similar to those seen in HIV and hepatitis C. But the New Jersey biotech will be competing with some deep-pocketed competitors in the space.
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2020. Data provided by Biomedtracker.